Detalhe da pesquisa
1.
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia.
Blood
; 130(23): 2499-2503, 2017 12 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28972014
2.
A combinatorial screen of the CLOUD uncovers a synergy targeting the androgen receptor.
Nat Chem Biol
; 13(7): 771-778, 2017 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-28530711
3.
Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia.
Haematologica
; 106(8): 2251-2256, 2021 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626863
4.
Systematic characterization of BAF mutations provides insights into intracomplex synthetic lethalities in human cancers.
Nat Genet
; 51(9): 1399-1410, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31427792
5.
Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations.
EMBO Mol Med
; 9(4): 498-507, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28264936
6.
TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML.
Oncotarget
; 8(14): 23061-23072, 2017 Apr 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28416739
7.
Acquired nintedanib resistance in FGFR1-driven small cell lung cancer: role of endothelin-A receptor-activated ABCB1 expression.
Oncotarget
; 7(31): 50161-50179, 2016 Aug 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27367030
8.
A strand-specific switch in noncoding transcription switches the function of a Polycomb/Trithorax response element.
Nat Genet
; 46(9): 973-981, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25108384